Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Oligodendroglioma 2Astrocytoma 2Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × talampanel × CNS × Clear all
NCT00267592 2016-05-19

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
72 enrolled
CNS

Glioblastoma

NCT00064363 2012-03-08

Talampanel in Treating Patients With Recurrent High-Grade Glioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00062504 2011-05-23

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
30 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡